| Name | Title | Contact Details |
|---|---|---|
John Loftis |
Chief Technology Officer | Profile |
Chris McLaurin |
Chief Technology Officer | Profile |
Access Health Care P.A. is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CME was founded in 1978 by psychiatrist John Schwartz, whose vision was to provide high-quality, practical continuing medical education and information for mental health clinicians throughout the United States. In its first decade, CME successfully
Med-El Corporation is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Signify Health exists to drive more healthy, happy days at home. That`s why we`re committed to accelerating the movement to value-based care, transforming how care is paid for and delivered, and sharing accountability for driving better outcomes for the individuals and families we all serve. Today, Signify Health is privileged to impact the lives of millions of people every year. Our high-performance provider and community networks—which includes the nation`s largest field-based network of doctors and nurse practitioners—reaches and engages people anywhere in the U.S. With powerful analytics and clinical expertise, we support individuals` health journeys from the acute care facility to the ideal next site of care and all the way to a place of residence, helping them get home sooner and stay there longer. This is how we`re transforming a fragmented healthcare system into one that`s value-based, human-centered, and drives more healthy and happy days at home.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.